This database was established to allow investigation of biomarkers associated with the transition from hormone naïve to castrate resistant prostate cancer.

Safehaven number: GSH/18/ON/009

109 patients with hormone-naïve and castrate resistant tumour pairs were included within this database (diagnosed between 1984 and 2000 with locally advanced or metastatic CaP from Greater Glasgow and Clyde Health Board). 

Patients were selected based on their response to hormone treatment (sub-capsular bilateral orchi- dectomy or LHRH agonists combined with anti-androgens) and their relapse (two rises in PSA > 10%). 

Hormone Naïve tissue was obtained via trans-rectal ultrasound guided biopsies and Castrate resistant tissue was obtained by transurethral resection of the prostate as a result of relieving bladder outflow obstruction.   

Clinical data included age, Gleason score, serum PSA levels at diagnosis, biochemical recurrence, serum PSA at biochemical recurrence and presence of metastases. 

Study end points were biochemical relapse, survival from biochemical relapse and disease-specific survival.

Ethical approval was acquired from Multicentre Research Ethics Committee for Scotland (MREC/01/0/36) and Local Research and Ethics Committees.